Top 50 Medical Startup Investors in Belgium (August 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Meusinvest (Noshaq)
VC Fund
|
12 | Belgium, France, Germany | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $137k–$31M |
|
Capricorn Partners
VC Fund
|
6 | Belgium, The Netherlands, United States | Series A, Series B | Biotechnology, Health Care, Software | $3.3M–$42M |
|
Newton Biocapital
VC Fund
|
5 | Belgium, Japan, France | Series A, Seed | Biotechnology, Medical, Health Care | $2.7M–$84M |
|
Limburgse Reconversie Maatschappij
VC Fund
|
5 | Belgium, The Netherlands, United States | Seed, Series A | Information Technology, Software, Biotechnology | $494k–$11M |
|
V-Bio Ventures
VC Fund
|
5 | Belgium, France, United States | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.1M–$88M |
|
Gemma Frisius Fund
VC Fund
|
4 | Belgium, France, United Kingdom | Seed, Series A, Series B | Biotechnology, Medical, Health Care | $634k–$84M |
|
White Fund
VC Fund
|
4 | Belgium, United States | Seed, Series A, Venture - Series Unknown | Health Care, Medical, Medical Device | $4.1M–$12M |
|
Qbic Fund
VC Fund
|
4 | Belgium, The Netherlands | Seed, Series A | Biotechnology, Software, Health Care | $906k–$28M |
|
S.R.I.W.
VC Fund
|
4 | Belgium, United States, Spain | Series A, Series B | Health Care, Biotechnology, Manufacturing | $411k–$75M |
|
Annie Vereecken
Angel
|
4 | Belgium | Seed, Series A | Medical, Biotechnology, Hospital | $2M–$30M |
|
GoBeyond
VC Fund
|
3 | Switzerland, Germany, United Kingdom | Seed, Series A | Information Technology, Medical, Software | $544k–$10M |
|
Mérieux Equity Partners
VC Fund
|
3 | France, United States, Belgium | Series A, Private Equity | Health Care, Biotechnology, Medical Device | $5.7M–$150M |
|
PMV
VC Fund
|
3 | Belgium, United States, The Netherlands | Seed, Series A, Series B | Software, Biotechnology, Health Care | $1M–$42M |
|
WING by Digital Wallonia
VC Fund
|
3 | Belgium | Seed, Series A, Convertible Note | Software, Health Care, Information Technology | $219k–$11M |
|
Fund+
VC Fund
|
3 | Belgium, United States, Spain | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$401M |
|
Forbion Capital Partners
VC Fund
|
2 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $16M–$180M |
|
Be Angels
VC Fund
|
2 | Belgium, France, Luxembourg | Seed, Pre-Seed | SaaS, Software, Information Technology | $78k–$1.5M |
|
Dental Innovation Alliance
VC Fund
|
2 | United States, Belgium, Germany | Seed, Series A | Dental, Health Care, Software | $1.8M–$5.5M |
|
KBC
VC Fund
|
2 | Belgium, United States, The Netherlands | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Software | $425k–$65M |
|
Buysse & Partners
VC Fund
|
2 | Belgium, United Kingdom, The Netherlands | Series A, Seed, Venture - Series Unknown | Software, Cloud Computing, FinTech | $1.1M–$11M |
|
Thuja Capital
VC Fund
|
2 | The Netherlands, Belgium, United States | Series A, Seed | Biotechnology, Medical, Health Care | |
|
BAN Vlaanderen
VC Fund
|
2 | Belgium | Seed, Series A | Health Care, Medical, Apps | $544k–$1.9M |
|
Spinventure
VC Fund
|
2 | Belgium | Series A | Health Care, Biotechnology, Medical | $768k–$15M |
|
BioGeneration Ventures
VC Fund
|
2 | The Netherlands, United States, Belgium | Series A, Seed | Biotechnology, Therapeutics, Health Care | $1.1M–$86M |
|
Inventures SA
VC Fund
|
2 | Belgium, France, United Kingdom | Series A, Seed | Health Care, Biotechnology, Manufacturing | $82k–$14M |
|
Noshaq
VC Fund
|
2 | Belgium | Series A, Venture - Series Unknown | Medical, Analytics, Health Care | |
|
Flanders Future Techfund
VC Fund
|
2 | Belgium, The Netherlands | Seed, Series A, Venture - Series Unknown | Medical, Biotechnology, Clinical Trials | $2.7M–$30M |
|
Sambrinvest
VC Fund
|
2 | Belgium, France, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $544k–$46M |
|
Volta Ventures
VC Fund
|
2 | Belgium, The Netherlands, United States | Seed, Series A, Pre-Seed | Software, Information Technology, SaaS | $850k–$10M |
|
Omnes Capital
VC Fund
|
2 | France, Germany, United States | Series A, Series B | Software, Biotechnology, Health Care | $3.5M–$53M |
|
Virginie Saverys
Angel
|
1 | Belgium | Seed | Medical, Life Science, Biotechnology | |
|
Annemie Van de Casteele
Angel
|
1 | Belgium | Seed | Medical, Life Science, Biotechnology | |
|
Yves Berquin
Angel
|
1 | Belgium | Seed | Medical, Health Care, Information Technology | |
|
Limburg Startup
VC Fund
|
1 | The Netherlands, France, Belgium | Series A, Series B | Biotechnology, Life Science, Health Care | |
|
TCD Capital (ex TheClubDeal)
VC Fund
|
1 | Belgium, France | Series A, Series B, Seed | Health Care, Biotechnology, Information Technology | |
|
Jean Dessain
Angel
|
1 | Belgium | Angel | Medical, Health Care, Biotechnology | |
|
Manuardeo
VC Fund
|
1 | Belgium | Series A, Series B | Medical, Diabetes, Health Care | |
|
Ifoghas Investments
VC Fund
|
1 | Belgium | Series A | Medical, Health Care, Life Science | |
|
imec.xpand
VC Fund
|
1 | Belgium, United States, Germany | Seed, Series A, Series B | Semiconductor, Manufacturing, Medical Device | $3.3M–$100M |
|
Debiopharm Innovation Fund
VC Fund
|
1 | United States, Switzerland, France | Series A, Seed, Pre-Seed | Health Care, Biotechnology, Software | $317k–$25M |
|
New Science Ventures
VC Fund
|
1 | United States, United Kingdom, Belgium | Series B, Series A, Series D | Biotechnology, Health Care, Medical | $4M–$52M |
|
Gimv
VC Fund
|
1 | Belgium, United States, France | Series B, Private Equity | Biotechnology, Health Care, Medical | |
|
BIP Investment Partners
VC Fund
|
1 | Belgium | Series A, Series B | Video, Medical, Software | |
|
EQT Life Sciences
VC Fund
|
1 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | |
|
Quest for Growth
VC Fund
|
1 | Belgium, France, The Netherlands | Series B, Series C | Biotechnology, Hardware, Software | |
|
Financière Spin-Off Luxembourgeoise
VC Fund
|
1 | Belgium | Series A | Medical, Health Care, Medical Device | |
|
LeanSquare
VC Fund
|
1 | Belgium, France, United States | Seed, Series A | Software, Music, Internet | |
|
Sofinnova Investments
VC Fund
|
1 | United States, France, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | |
|
Sofinnova Partners
VC Fund
|
1 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | |
|
NV Industriebank LIOF
VC Fund
|
1 | The Netherlands, Belgium | Series A, Seed | Biotechnology, Medical, Health Care | |
| Access all 169 investors in Belgium Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 78
- Round size: Seed $137k–$6M; Series A $3.6M–$16M; Series B $680k–$31M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 120
- Round size: Series A $3.3M–$18M; Series B $5.3M–$42M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Sensolus — Sensolus provides care-free tracking of your valuable non-powered assets directly from the cloud.Sensolus offers turnkey solutions for wireless, low-power context-aware sensing. Sensolus developed a personal product line of low-power tracker systems called STICKNTRACK.Sensolus is built upon many years of expertise in low-power networks,wireless sensor design, cloud-based sensor management, analytics, and applications.
- Endo Tools Therapeutics — Endo Tools Therapeutics is dedicated to the development of innovative devices that provide therapeutic interventions for gastric conditions
- Delft Advanced Biorenewables — We enable the bio-economy by improving the productivity of fermentations with our in-situ product recovery (ISPR) technology.
Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: Belgium, Japan, France
Investor stats
- Total investments: 22
- Round size: Seed $2.7M–$3.2M; Series A $6.1M–$84M
- Lead/follow: 68% lead, 32% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Bioxodes — Bioxodes is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics to prevent thrombotic events without hemorrhagic risk.
- Tensegrity Pharma — Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.
- Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.
Oxygen for growth - LRM
Show more...Investment focus
- Industry: Information Technology, Software, Biotechnology
- Stage:Seed, Series A
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 97
- Round size: Seed $494k–$5.2M; Series A $1.6M–$11M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Monsana — Monsana's AI-powered platform empowers both patients and healthcare professionals in their search for the perfect clinical trial. Each eligibility criterion is validated based on your unstructured textual medical records, allowing highly accurate matching with experimental treatments.
- ADLC — ADLC employs drone technology to deliver logistics services, allowing businesses to implement drone-based solutions without having to manage them in-house. The company is focused on enhancing last-mile delivery in maritime and offshore environments. ADLC now conducts drone delivery services in the Port of Antwerp in collaboration with SGS, atesting and certification company, and works with companies such as BASF. Its drones have reduced delivery times and environmental effect, boosting efficiency sixfold and lowering CO2 emissions by up to 80% for petrochemical sample deliveries.
- Optiflux — Optiflux automatiseert het bewaarbeheer van vers fruit met slimme AI & vision-technologie. Minder verlies, meer winst voor teler & handelaar.
V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: Belgium, France, United States
Investor stats
- Total investments: 44
- Round size: Seed $3.1M–$50M; Series A $6.6M–$70M; Series B $12M–$88M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — raised $129M in 2021
Portfolio highlights
- Animab — Animal Health Company
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- Biodol Therapeutics — Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (CyrilRivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.
Gemma Frisius Fund KU Leuven is a seed capital fund that aims to stimulate the creation and growth of university related spin-off companies.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A, Series B
- Geography: Belgium, France, United Kingdom
Investor stats
- Total investments: 40
- Round size: Seed $634k–$4.6M; Series A $932k–$84M; Series B $4.7M–$24M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Runeasi — The first scientifically validated wearable solution to measure impact while running and detect how your body responds to it - Perform real-time biomechanical assessments - Guide your athletes and patients with actionable insights to help them run more efficiently and recover from injuries with confidence
- Optiflux — Optiflux automatiseert het bewaarbeheer van vers fruit met slimme AI & vision-technologie. Minder verlies, meer winst voor teler & handelaar.
- Aspect Analytics — Beyond bioinformatics. Building intelligent platform solutions for mass spectrometry imaging data analysis. #AI4MSI
For game changers in medtech
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Belgium, United States
Investor stats
- Total investments: 12
- Round size: Seed $4.1M–$11M; Series A $5.3M–$12M; Venture - Series Unknown $5.5M–$11M
- Lead/follow: 67% lead, 33% follow
- Last fund: May invest from a new fund soon — raised $23M in 2019
Portfolio highlights
- neuroClues — An easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam
- Minze Health — Minze Health is a health tech start-up that builds creative digital health solutions for urology, pelvic health, and (in)continence care.
- Clouds of care — Increasing your probability of success through the adoption of meaningful endpoints, starting from electrophysiology.
The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Ourinvestment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support.In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series A
- Geography: Belgium, The Netherlands
Investor stats
- Total investments: 61
- Round size: Seed $1.3M–$7.4M; Series A $906k–$28M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $57M in 2022
Portfolio highlights
- Firecell — Firecell is a Telecommunications Industry.
- Eyeo — eyeo revolutionizes imaging with color splitter sensors. Capture sharper, brighter images in low light using optical waveguide innovation, discover how it works
- Sightera Biosciences — Revolutionizing drug discovery through AI-powered analysis of patient-derived models for breakthrough therapeutics in cancer and regenerative medicine.
The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the Société Régionaled’Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Series B
- Geography: Belgium, United States, Spain
Investor stats
- Total investments: 111
- Round size: Series A $411k–$31M; Series B $1.6M–$75M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Univercells — Mix parlay, atau lebih dikenal sebagai parlay bola atau hanya parlay, merupakan taruhan judi bola online yang menggabungkan minimal 2 hingga 10 tim pertandingan sepak bola menjadi 1 tiket taruhan.
- Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
- Santero Therapeutics — This is the homepage of the website
Annie Vereecken
Show more...Investment focus
- Industry: Medical, Biotechnology, Hospital
- Stage:Seed, Series A
- Geography: Belgium
Investor stats
- Total investments: 7
- Round size: Seed $2M–$6M; Series A $8.2M–$30M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
- LynxCare — Continuously improving patient outcomes with previously unavailable insights. Find out more here.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Industry: Information Technology, Medical, Software
- Stage:Seed, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 164
- Round size: Seed $544k–$5M; Series A $1.2M–$10M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Stylect — Stylect is a mobile app to to help women discover their perfect shoe. They aggregate products from multiple websites and based on users' preferences (that they gather through a hot-or-not interface), they recommend better products. Their users are able to keep track of and buy the products they like and receive notifications whenever a productthey love goes on sale. Finally, They use geolocation to let their users know when a shoe is selling in a store nearby.
- Prestodiag — Prestodiag develops, manufactures and sells innovative solutions for rapid detection of bacteria. Their analytical solutions are based on an innovative optics technology called Surface Plasmon Resonance imaging and allow detection and identification of pathogenic bacteria such as Salmonella, Listeria or E.coli. They provide users with a result injust a few hours instead of 1 to several days. Their market is primarily the food safety sector, and also on medical and environmental applications.
- Arktis Radiation Detectors — Arktis develops and manufactures next generation systems that detect and categorize radiological and nuclear materials to enhance security and operations.
Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Private Equity
- Geography: France, United States, Belgium
Investor stats
- Total investments: 57
- Round size: Series A $5.7M–$23M; Private Equity $22M–$150M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — raised $417M in 2020
Portfolio highlights
- DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
- Ceva Santé Animale — Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. FromUganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.
- CorFlow Therapeutics — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.
Do and dare company
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 156
- Round size: Seed $1M–$3.8M; Series A $2.7M–$40M; Series B $6.6M–$42M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
- Borro — Cashless deposit system
- Storm — Storm is een producent van hernieuwbare energie. Samen met ons team ontwikkelen, bouwen en exploiteren we duurzame energieprojecten over het hele land: van wind- en zonneparken tot snellaadstations en batterijopslag. Dit telkens tegen een zo laag mogelijke maatschappelijke kost.
W.IN.G by Digital Wallonia invests in SAAS, advanced tech and deep tech startups (AI, drones, medtech, IOT,...). W.IN.G brings smart money by helping startups by bi-weekly interactions and providing an operating teams (seasonal entrepreneurs being hands-on with the portfolio).
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A, Convertible Note
- Geography: Belgium
Investor stats
- Total investments: 34
- Round size: Seed $346k–$1.9M; Series A $1.1M–$11M; Convertible Note $219k–$555k
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- IONNYK — IONNYK is a new medium of art photography, containing millions of tiny ink capsules.
- MYOCENE — Myocene is a Liège-based sports technology company which creates unique and innovative devices for measuring muscle fatigue and performance.
- Soil Capital Belgium — Discover Europe's first certified, multi-national carbon farming programme that rewards regenerative agriculture.
Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.Fund+ was established in 2015 and is based in Leuven, Belgium.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Belgium, United States, Spain
Investor stats
- Total investments: 32
- Round size: Series A $11M–$46M; Series B $22M–$125M; Series C $11M–$401M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 208
- Round size: Series A $19M–$180M; Series B $16M–$155M; Series C $19M–$120M
- Lead/follow: 52% lead, 48% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Inflazome — Situs gacor premium Megawin188 paling banyak di minati oleh semua kalangan karena pecah selayar tanpa henti dan memiliki tampilan yang sangat memanjakan mata.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Early stage Entrepreneurs Coaching and FinancingOne of Europe's leading Business Angels Networks. We connect innovative growth companies to equity finance and coaching by experienced angel investors. The network is 250 members strong and has been assisting innovative entrepreneurs to find financing for more than 10 millions Euros in thelast 4 years.
Show more...Investment focus
- Industry: SaaS, Software, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Belgium, France, Luxembourg
Investor stats
- Total investments: 25
- Round size: Seed $247k–$1.5M; Pre-Seed $78k–$571k
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- ChainComply — ChainComply provides enhanced KYT due diligence solutions for banks and VASPs and relieves them from stressing over incoming transfers from crypto exchanges. ChainComply develops a SaaS tool that scans the client's crypto exchange and blockchain transaction history to reveal the source of funds of crypto holders. The company solutionsimplifies complex transaction streams, and then it identifies high-risk transactions and patterns, enabling AML teams to understand their clients better and meet regulatory obligations efficiently.
- Visiblie — Track and optimize your brand across ChatGPT, Claude, Gemini, and Perplexity. Monitor AI mentions, analyze competitors, and grow AI search visibility.
- TalentGuide — Unlock workforce potential with Talentguide's skills intelligence platform, transforming ambition into measurable ability through actionable insights and personalized development paths.
Dental Innovation Alliance (DIA) is a venture capital company that invests in, advises on, and accelerates the growth of early-stage companies that are transforming dentistry through technology.
Show more...Investment focus
- Industry: Dental, Health Care, Software
- Stage:Seed, Series A
- Geography: United States, Belgium, Germany
Investor stats
- Total investments: 11
- Round size: Seed $1.8M–$2.1M; Series A $4.5M–$5.5M
- Lead/follow: 73% lead, 27% follow
Portfolio highlights
- Relu — Integrate Relu's automatic 3D segmentations seamlessly into your CBCT software.
- Alta Smiles — Alta Smiles provides patent-pending orthodontic clinical support solutions. It is driven by a mission to make orthodontic and oral care solutions more accessible and convenient through innovation and technology.
- Perceptive — Developer of an image-guided robotic restorative dentistry platform for crowns and fillings. CYBERDONTICS enables dentists to identify, remove and restore tooth decay with higher precision than is currently possible using human senses and human hands. CYBERDONTICS adds capacity to dental clinics. For patients, CYBERDONTICS aims to provide superiorrestorations at a lower cost and in less time.
KBC Private Equity - the investment company of KBC Group - provides development capital and finances buy-outs to medium-sized companies in Belgium and in Central and Eastern Europe, KBC's home markets.Boasting an experienced team of 28 people, it has more than 60 active investments in portfolio with a market value in excess of EUR 400million.KBC Private Equity aims to become one of the leading private equity providers on KBC Group's home markets. As an active shareholder with a long-term perspective, KBC Private Equity is involved in taking strategic decisions and providing support to management teams.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Pre-Seed
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 36
- Round size: Seed $549k–$8M; Pre-Seed $425k–$1.9M; Series A $3M–$65M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Rookoo — Rookoo is AI-powered venue management software that automates event inquiries, checks availability, and books events 24/7. Used by Clays, Tour & Taxis, Wintercircus and more.
- Qivalis — Qivalis is a financial technology company designed for payments, settlements, and financial services.
- Ion Beam Applications — Ion Beam Applications is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticalssegment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry.
Buysse and Partners is a private equity investment group based in Antwerpen that offers smart equity, a growth fund, and partnerships.
Show more...Investment focus
- Industry: Software, Cloud Computing, FinTech
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Belgium, United Kingdom, The Netherlands
Investor stats
- Total investments: 6
- Round size: Seed $1.1M–$2M; Series A $3.9M–$11M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $23M in 2012
Portfolio highlights
- Twikit — Deliver unforgettable customer experiences with real time 3D product configurators, linked to your existing order and manufacturing flows.
- Bluebee — Delivering a streamlined way for users to analyze, explore, and manage large-scale genomics data in the cloud.
- moonbird — Hold moonbird in your hand and breathe along. A tactile, screen-free breathing coach trusted by 80,000+ users for less stress, better sleep, and more calm.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Thuja Capital invests in early stage medical product innovations for diagnosis, cure, care or prevention.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: The Netherlands, Belgium, United States
Investor stats
- Total investments: 54
- Lead/follow: no public data
Portfolio highlights
- Pan Cancer — Pan Cancer T is an immunotherapy company developing next-generation TCR-T cell therapies for solid cancer.
- Synerkine Pharma — Synerkine Pharma. Connecting Cytokines for the benefit of patients.
- Artica Therapeutics — Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food.
BAN Vlaanderen is the business angel network in Flanders, a value-added platform within which new or growing businesses are brought into contact with informal private investors, called Business Angels. Looking for venture capital This Business Angels bring not only money but also their own know-how, experience and contacts. Are connecting servicesoffered. Both the entrepreneurs and the business angelsBAN Vlaanderen is no investment, it does not own shares or take any investment decisions, nor for its own account or on behalf of the affiliates. Instead, it is a market where supply and demand are brought together. The information on this site is intended to initiate the purpose and operation of BAN Vlaanderen. For more information you can always contact one of our regional offices.BAN Vlaanderen is an association that aims to stimulate the development, support and promotion of entrepreneurship and investment culture in Belgium. Economic growth in Belgium
Show more...Investment focus
- Industry: Health Care, Medical, Apps
- Stage:Seed, Series A
- Geography: Belgium
Investor stats
- Total investments: 7
- Round size: Seed $544k–$1.9M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- OutKept — Can you be phished? Verhoog je bewustzijn en naleving met volledig geautomatiseerde phishing-simulaties gemaakt door een community van ethische phishers.
- Pom — POM stands for Peace of Mind. And it's exactly that worry-free feeling that they want their customers to achieve through their invoice management solutions, both for the receiver and the sender.Their goal is to eliminate the senseless time and effort spent because of inefficient systems. And thus freeing up time to do the things that reallymatter.
- Oncomfort — Oncomfort’s solution for digital sedation is a completely new method for relieving patients’ pain and anxiety before, during and after medical procedures. This revolutionising digital therapy combines clinical hypnotherapy and integrative therapeutic techniques through Virtual Reality.
Spinventure supports the creation of spin-off companies that aim to industrialize and commercialize the result of scientific research. Spinventure was born from a collaboration between MEUSINVEST and the University of Liège. It is headquartered in Angleur, Belgium.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A
- Geography: Belgium
Investor stats
- Total investments: 6
- Round size: Series A $768k–$15M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Dim3 — Improve patients outcome - Deliver actionable insights - Save healthcare costs
- Elysia — Elysia developed solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals.
- Convert Pharmaceuticals — Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors.
Shaping new life-science ventures.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Health Care
- Stage:Series A, Seed
- Geography: The Netherlands, United States, Belgium
Investor stats
- Total investments: 65
- Round size: Seed $1.1M–$50M; Series A $5.3M–$86M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $148M in 2021
Portfolio highlights
- Dualyx — Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
- Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
- Noviogendix Holding — NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer. NovioGendix, based in Nijmegen (The Netherlands), is a molecular diagnostic company providing an expert-based, integrated approach in developing advanced and clinically useful molecular diagnosticassays for uro-oncological practice. NovioGendix has a range of diagnostic tests for prostate, bladder, kidney and other urologic cancers in various stages of development. Commencing activities in 2008 as a Radboud University Medical Center (Radboudumc) spin-off company, NovioGendix has a standing cooperation with various Radboudumc departments. The main shareholders of NovioGendix include BioGeneration Ventures, and Participatiemaatschappij Oost Nederland.
Inventures is a European venture capital fund that builds a better world through a portfolio of investments in sustainable businesses.The firm has two funds: Inventures I & Inventures II.Inventures was created to support early stage smart and innovative European businesses, to support sustainable job growth and empower entrepreneurs.Inventures empowers citizenship co-investments through a crowdfunding platform, MyMicroInvest.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Seed
- Geography: Belgium, France, United Kingdom
Investor stats
- Total investments: 46
- Round size: Seed $82k–$2.1M; Series A $411k–$14M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- BiOceanOr — BiOceanOr harnessed the power of Marine Biology and AI to deliver bio-guided services that optimize fish welfare and fish growth, while supporting aquaculture sustainability standards
- myskillcamp — Myskillcamp is a digital learning platform and educational design support service. Myskillcamp supports their customers in the digital transformation of their company and the launch of their Digital Learning project. From the audit of needs to the design of engaging educational devices, through a pilot phase, they make a point of honor to adapt thedigital to the specificities of each and give it meaning.With their online platform, businesses can manage their learner communities and connect all their partners in one place. Their tool also allows businesses to structure training spaces by skills, trades, brands within camps. In parallel, businesses can create educational content from scratch, select a map in their marketplace, or plan sessions in-class. Businesses can organize the distribution of their training to a single learner or to a whole group.
- Octave — Optimize energy use with Octave's battery storage (BESS) and energy management system (EMS). Reduce costs, increase flexibility.
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Medical, Analytics, Health Care
- Stage:Series A, Venture - Series Unknown
- Geography: Belgium
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- MyCellHub — MyCellHub.com is a pre-startup from the KULeuven in the biotherapeutics industry that aspires to reform the way cell production processes are organised. With a regulatory compliant Saas-platform for data management and analytics, we increase the efficiency of your manufacturing processes, provide actionable insights via cell culture specificprocess analytics and facilitate regulatory compliance by means of a real-time audit trail and automated batch records.
- DeuterOncology — DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies.
- Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
Flanders Future Techfund operates as an investment firm.
Show more...Investment focus
- Industry: Medical, Biotechnology, Clinical Trials
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Belgium, The Netherlands
Investor stats
- Total investments: 7
- Round size: Seed $2.7M–$30M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- EDGX — EDGX, founded in 2023 in Ghent, is a Belgian Space Tech company developing high-speed edge computing units for satellites. Its NVIDIA-powered Sterna Computer and SpaceFeather software enable real-time, AI-driven on-orbit data processing for applications in communication, Earth observation, and intelligence.
- Flindr Therapeutics — Immagene develops personalized cancer immunotherapies to fight multiple cancer type.
- Clouds of care — Increasing your probability of success through the adoption of meaningful endpoints, starting from electrophysiology.
Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: Belgium, France, Spain
Investor stats
- Total investments: 40
- Round size: Seed $544k–$24M; Series A $987k–$46M; Series B $4.4M–$45M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Brenus Pharma — Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment.
- Vertical Compute — Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings.
- Enodia Therapeutics — Enodia Therapeutics pioneers targeted protein degradation at the Sec61 translocon, developing small-molecule therapies for inflammatory and autoimmune diseases.
Volta Ventures backs ambitious B2B software founders in the Benelux with early-stage capital, strategic guidance and long-term support.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Series A, Pre-Seed
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 91
- Round size: Seed $850k–$5.2M; Pre-Seed $1M–$3M; Series A $2.2M–$10M
- Lead/follow: 49% lead, 51% follow
- Last fund: May invest from a new fund soon — raised $72M in 2019
Portfolio highlights
- Kyvvu — Kyvvu is an Agent Security Kernel (ASK): an in-process security layer that checks every action an AI agent takes — against the full path of the task so far — and allows, warns, or blocks it before it runs, deterministically, in under a millisecond, without your data ever leaving your environment.
- Nodalview — Nodalview helps real estate agents deliver cutting edge content and an impressive buying experience for happy and loyal customers.
- CHILI publish — Allow users to edit customizable documents, or fully automate artwork generation. Output files are ready to use for print and digital.
Omnes Capital takes a unique approach to renewable energy, transforming developers into independent power producers to provide green energy to millions.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B
- Geography: France, Germany, United States
Investor stats
- Total investments: 184
- Round size: Series A $3.5M–$41M; Series B $4.4M–$53M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $403M in 2020
Portfolio highlights
- VSORA — VSORA provides high performance companion solutions combining AI and signal processing to enable autonomous driving and ADAS
- SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Virginie Saverys is a entrepreneur.
Show more...Investment focus
- Industry: Medical, Life Science, Biotechnology
- Stage:Seed
- Geography: Belgium
Investor stats
- Total investments: 1
- Lead/follow: no public data
Annemie Van de Casteele is a former member of the Belgian Parliament.
Show more...Investment focus
- Industry: Medical, Life Science, Biotechnology
- Stage:Seed
- Geography: Belgium
Investor stats
- Total investments: 1
- Lead/follow: no public data
Yves Berquin is the Co-Founder and Co-CEO of Matrix Requirements. He attended Free University of Brussels. .
Show more...Investment focus
- Industry: Medical, Health Care, Information Technology
- Stage:Seed
- Geography: Belgium
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- Salvus Health — Salvus Health is het platform voor preventieve en farmaceutische diensten in de apotheek.
Limburg Ventures is a venture capital fund that invests in startups in life sciences and related fields of advanced chemicals and materials.
Show more...Investment focus
- Industry: Biotechnology, Life Science, Health Care
- Stage:Series A, Series B
- Geography: The Netherlands, France, Belgium
Investor stats
- Total investments: 13
- Lead/follow: no public data
Portfolio highlights
- FABPulous — FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, HealthInnovations, Limburg Ventures and NV Industriebank LIOF.The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction.
- Kriya Materials — Kriya Materials is the innovative developer and manufacturer of various metal oxide nano particles as well as their downstream dispersions and functional coating products thereof. Coatings play an important role in our everyday life, although often not recognized by those who do not master the art. Coatings are a big market and many products fallunder this category. Kriya Materials focuses itself on the development and manufacturing of various nano metal oxides which it uses internally for the development and production of very high end coatings.The coatings made by Kriya Materials are applied in a wide range of markets, some examples are the Plasma Panel and LCD industry, from Smartphone to touch panels to glass surfaces.
- ReSolved Technologies — ReSolved Technologies are dedicated to increase the circularity of engineering plastics by addressing complex waste streams. They do this by extracting valuable plastics from these difficult-to-recycle waste streams and convert them to recycled material of near-virgin quality that is suited for closed-loop recycling in high-end markets.
TheClubDeal is an investment holding and fund manager co-investing into SME’s and real estate projects. It provides facilitation of governance between non-executive shareholders and entrepreneurs. Its governance structure, including its charter of avoidance of conflict of interests, is therefore paramount to the adequate management of the Company.At TheClubDeal, we connect Investors and Entrepreneurs around promising investment opportunities. For each of these, we will invest ourselves and co-invest with a selected number of investors. We add value by processing strong applied governance principles, when selecting and managing our investments, and by gathering the necessary skills to successfully grow the businesses and real-estate projects we co-invest in. TheClubDeal is launching their second fund, a 50M € PRIVAK/PRICAF in H1 2021 with the mandate to invest in Belgian scale-ups in three sectors: Smart Living, Tech and Life Sciences.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Information Technology
- Stage:Series A, Series B, Seed
- Geography: Belgium, France
Investor stats
- Total investments: 17
- Lead/follow: no public data
Portfolio highlights
- Vaxinano — Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder.
- Inpulse — Inpulse is an automated supply management platform for restaurateurs.
- Clouds of care — Increasing your probability of success through the adoption of meaningful endpoints, starting from electrophysiology.
Jean Dessain - Non Executive Director @ OneLIFE
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Angel
- Geography: Belgium
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- OneLIFE — Enzymatic cleaning solutions against soiling and biofilms for medical devices and the hospital environment. Safe for staff, patients and visitors.
Manuardeo is an early stage investments focused VC firm.
Show more...Investment focus
- Industry: Medical, Diabetes, Health Care
- Stage:Series A, Series B
- Geography: Belgium
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Indigo Diabetes — Revolutionizing the management of chronic disease.
Ifoghas Investments operates as an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Series A
- Geography: Belgium
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Expanding nanotechnology into business.
Show more...Investment focus
- Industry: Semiconductor, Manufacturing, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Belgium, United States, Germany
Investor stats
- Total investments: 52
- Round size: Seed $3.3M–$23M; Series A $8.7M–$56M; Series B $12M–$100M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — raised $351M in 2024
Portfolio highlights
- Pharrowtech — Pharrowtech designs next-generation solutions for fixed-wireless access, wireless VR/AR and ultra-high capacity wireless links. It builds on more than 12 years of top-notch R&D performed at imec, the Belgian R&D powerhouse. Leveraging deep technical expertise in algorithm, chip and antenna design for millimeter-wave systems, it createsproducts with best-in-class performance, power and cost features.
- Spectricity — Spectricity provides multispectral imaging solutions to enhance color accuracy and analysis capabilities in mobile and consumer electronics.
- Swave Photonics — Swave develops Spatial Computing, Holography, holographic chips, and holograms in the HXR chip to create 3D augmented and virtual reality and HUD Heads Up Displays
Debiopharm invests in Smart Data & Digital Health companies developing technologies that are applicable in the areas of oncology or infectious diseases
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Seed, Pre-Seed
- Geography: United States, Switzerland, France
Investor stats
- Total investments: 46
- Round size: Seed $943k–$6M; Pre-Seed $317k–$1.7M; Series A $3.5M–$25M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- Octozi — AI agents that accelerate clinical development. Automate data cleaning, review, reconciliation, and reporting across your trials.
- ModernVivo — New drugs fail in human clinical trials 90% of the time. These failures can be traced directly back to the consistent inability of preclinical animal studies to predict clinical success. Yet the design process for preclinical animal studies has remained largely unchanged for decades; scientists read a tiny fraction of published literature and writetheir experimental protocols in 2-4 weeks. This time-consuming, tedious process is not only a major pain point for in-vivo scientists but leads to substantial experimental design flaws, resulting in unreliable data with which billion-dollar decisions are made. Scientists we’ve spoken to repeatedly express their struggle with the overwhelming amount of preclinical information they need to sift through in order to design experiments. At ModernVivo, we are revolutionizing this antiquated process by equipping scientists with tools that enable them to write in-vivo protocols more effectively. Our technology empowers scientists to streamline their work, accelerating drug development timelines.
- MedaSystems — Streamline patient and provider inquiries for Expanded Access or Compassionate Use with secure, 21st Century Cures Act compliant, cloud software.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series D
- Geography: United States, United Kingdom, Belgium
Investor stats
- Total investments: 87
- Round size: Series A $4M–$49M; Series B $8M–$52M; Series D $5M–$38M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $4.9M in 2020
Portfolio highlights
- EXTEN Technologies — EXTEN HyperDynamic software platform solves the primary challenges of today's data centers: the necessity of keeping up with surging data density, velocity, and volume requirements, and the need for increased application agility.
- BrightVolt — BrightVolt is an innovative manufacturer of solid-state thin & flexible lithium polymer batteries and power-efficient thin & flexible microelectronics for IoT clients. It specializes in the fields of battery, electronics, and manufacturing. BrightVolt got recapitalization in November 13, 2013.
- Trellis Bioscience — Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact ofpotential therapeutic interventions. The company is based in San Francisco, California.
Gimv, a trusted European investment company, helps mid-market businesses create sustainable value through growth capital and expertise across diverse sectors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Private Equity
- Geography: Belgium, United States, France
Investor stats
- Total investments: 155
- Lead/follow: no public data
Portfolio highlights
- Curana — Curana is a manufacturer of bike equipment and accessories.
- Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
BIP Investment Partners S.A. (BIP) is an independent financial holding company backed by Luxembourg family shareholders.Its activities are divided between providing private equity to businesses, particularly venture capital to startups, and investing in large, well-established Luxembourg-based businessesThe company was founded in 2000 as ajoint venture between Banque Générale du Luxembourg (BGL), later a part of Fortis Group, and now as the newly re-formed BGL and several smaller partners, under the name BGL Investment Partners, which was changed to 'BIP Investment Partners' in February 2006 after the rebranding of BGL. BIP is listed on the Luxembourg Stock Exchange, where it is one of the ten component companies of the main LuxX Index stock market index.
Show more...Investment focus
- Industry: Video, Medical, Software
- Stage:Series A, Series B
- Geography: Belgium
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- XDC — CinemaNext is the largest cinema integrator company in EMEA (installation, digital, content, Dolby Atmos, laser projectors, NOC, maintenance & support).
- Movetis — Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractorygastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 156
- Lead/follow: no public data
Portfolio highlights
- XyloCor Therapeutics — XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.
- Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
- Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.
Quest for Growth (QGPLF) is an Internet company located in 19 Lei, Leuven, Flanders, Belgium.
Show more...Investment focus
- Industry: Biotechnology, Hardware, Software
- Stage:Series B, Series C
- Geography: Belgium, France, The Netherlands
Investor stats
- Total investments: 24
- Lead/follow: no public data
Portfolio highlights
- Qpinch — Our patented QHT - Qpinch Heat Transformer - technology recovers and transforms waste heat into carbon neutral process heat.
- Finquest — Tap into the largest private company database in the world to change the way you find and connect with M&A targets using Data, AI, & People.
- Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Specializes in spin-off and spin-out investments.
Show more...Investment focus
- Industry: Medical, Health Care, Medical Device
- Stage:Series A
- Geography: Belgium
Investor stats
- Total investments: 1
- Lead/follow: no public data
Portfolio highlights
- Synergia Medical — Synergia Medical aims at developing and commercializing next generation neurostimulation devices. It relies on a seasoned management team with extensive experience in developing implantable neurostimulators.In only three years time, the company became ISO13485 certified, created and sold an OEM external neurostimulator for a motorized amputeeprosthesis arm and developed its first version of the NAOS platform.Supported by private investors and public research grants, the company has quickly grown to a team of thirteen highly skilled multidisciplinary professionals.
New Economy Startups Investor & Accelerator
Show more...Investment focus
- Industry: Software, Music, Internet
- Stage:Seed, Series A
- Geography: Belgium, France, United States
Investor stats
- Total investments: 41
- Lead/follow: no public data
Portfolio highlights
- Un:Hurd Music — Welcome to the one stop music marketing shop. We help you understand your audience before creating award winning release strategies.
- ClimateCamp — Looking for a sustainable way to collaborate with your suppliers on emissions reduction projects? Look no further than our platform - Book a demo for free!
- Base for music — Base for Music is the marketing solution specialized in fan acquisition, enabling you to achieve your growth goals and providing you with transparent da...
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, France, United Kingdom
Investor stats
- Total investments: 191
- Lead/follow: no public data
Portfolio highlights
- Aiolos Bio — Long Description: Aiolos Bio is a biotech company focused on developing therapies for respiratory diseases like asthma as well as other immune conditions. The company is initially focused on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma that only requires dosing every 6 months. Aiolos Bio was founded by anaccomplished team with decades of drug development experience and leadership in the biotech industry.
- Star Therapeutics — Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
- Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 219
- Lead/follow: no public data
Portfolio highlights
- Moon Surgical — MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.
- BrightHeart — BrightHeart develops an AI-based platform for fetal ultrasound analysis to improve detection of congenital heart defects.
- Alia Therapeutics — Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.
NV Industriebank LIOF is the Limburg development and investment company. LIOF contributes to the prosperity of the province with an ongoing program to strengthen the province's economic base. LIOF targets industry and the dynamic service sector.Its four core activities are Acquisition, Participation, Development/Innovation andBusiness Parks, as these relate to the location/relocation of (foreign) companies, venture capital participation in Limburg companies with prospects, the development/implementation of programs and projects to sharpen the competitive edge of Limburg business and the coordination of the development of new business parks.LIOF has a strategic approach which targets opportunities for long-term economic development. In this it has a bridging role between government and business. LIOF is an ambitious professional organization and speaks the language that business understands.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Seed
- Geography: The Netherlands, Belgium
Investor stats
- Total investments: 25
- Lead/follow: no public data
Portfolio highlights
- Ansana — Ansana develops sterilization solutions for the pharmaceutical and healthcare industries. This technology is significantly cutting patient risk, reducing the environmental imprint, lowering expenses, and increasing flow.
- Mosa Meat — Mosa Meat produces slaughter-free hamburgers. The burger is harvested from cow cells, rather than raising and slaughtering a whole animal. By growing meat naturally from cells, Mosa Meat strives to accelerate the transition to a truly sustainable global food system.
- SpecifAi Parking — Maximize your revenue, increase your efficiency and streamline your parking operation.
Medical Investor funding in Belgium at a glance
Stats across 125 deals from 169 investors.
Access all 169 investors in Belgium Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical Investors in Belgium investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 169 investors investing in Belgium Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!